Corline Biomedical AB (“Corline” or the “company”) has signed a letter of intent (Letter of Intent) with James Shapiro and The Clinical Islet Transplant Program at the Alberta university in Edmonton, Canada to evaluate a partnership for clinical studies in type 1 diabetes. Alberta is one of the most prominent öcellsprogrammen in the world, and Shapiro, published in the year 2000 the so-called Edmontonprotokollet, which demonstrated the revolutionary results with insulinfrihet of a large proportion of patients 5 years after transplantation. Corlines goal of the cooperation is to accelerate patient recruitment in the of the Swedish medical products agency approved the phase 1 study with Cytoparin(TM)-treated Islets of the islands, by increasing the number of clinical centers.
In öcellstransplantation for curing diabetes type 1, develops Corline product Cytoparin(TM), which aims to protect öceller against unwanted immunförsvarsreaktioner (IBMIR) and thus improve the efficacy of the treatment. Cytoparin(TM)-the project was approved by the medical products agency in Sweden for the start of the clinical study and patients are planned to be recruited by the clinical centers in Uppsala and Stockholm. In order to accelerate the recruitment of patients to the study has Corline initiated discussions with additional clinics both in and outside the Nordic countries. Corline has previously assessed that the interest for Cytoparin(TM) is large, which for a short time ago manifested itself in the concrete call university of Oxford, to participate in the study. The possibilities for Cytoparin(TM) to potentially become a general use technology on an international basis is further reinforced by the discussions on cooperation is maintained with the Alberta university in Edmonton, Canada.
The division of responsibilities within the proposed cooperation is to Corline transfer the technology to treat öceller with Cytoparin(TM), as well as providing regulatory support, while The Clinical Islet Transplant Program at the Alberta university implements Cytoparin(TM)-the treatment of öcellerna, and recruit and treat patients within the framework of the clinical study. Corline retains continued all the commercial rights related to the product. Technology transfer and contacts with regulatory authorities is scheduled to commence after the summer of 2017, at which time a formal agreement between the parties is expected to be in place.
Prof James Shapiro, comments on the
“W
e would be exceedingly fortunate to have this great opportunity to work closely with you and the Uppsala team in moving your very exciting first-in-man trial to the clinic. Controlling IBMIR effectively is the single most important intervention In the believe that will effectively turn islet engraftment around to the point where a single donor will successfully reverse diabetes in a robust and sustainable way. In further believe that this approach may accelerate ongoing advancements in stem cell engraftment. From my perspective, this will be a priority trial for us”.
Henrik Nittmar, PRESIDENT of Corline Biomedical AB, comments
“Once again, it is very positive for Cytoparin(TM) project and Corline that we are now initiating further dialogue about the collaboration with a leading centre for öcellstransplantation, this time in north America. One of the world’s absolute leading researchers in the field, James Shapiro, gives expression to a strong belief in our technology, which I regard as very satisfactory. It really feels like we are on the right track. Now we are working for a fast transfer of the documentation shall be reviewed by the relevant regulatory authorities”.
For questions, please contact
Henrik Nittmar, CEO
Telephone: 018-71 30 90
E-mail: henrik.nittmar@corline.se
Certified Adviser
Subsequently, the Brokerage is Corlines Certified Adviser.
This information is such information that Corline Biomedical AB is obliged to publish under the EU marknadsmissbruksförordning. The information was submitted, by the above contact person in the government, for publication on 03 July, 2017.
Corline Biomedical AB
working with the endogenous substance heparin and has developed a portfolio of candidate drugs for use in conjunction with organ – and cell transplantation. The company is planning clinical studies in type 1 diabetes and kidney transplant, for which the Corline also has received särläkemedelsstatus (“Orphan Drug”). Within the framework of a wholly owned subsidiary of Corline Pharma AB evaluated the in vivo administration of Corlines heparinsubstans.
170703_PM – Corline – Memorandum of understanding with the Alberta Unviersity_Shapiro
